Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Anti-CD20 antibodies for primary cutaneous B cell lymphoma. Preliminary results in dermatologic patients
Autore:
Gellrich, S; Muche, JM; Pelzer, K; Audring, H; Sterry, W;
Indirizzi:
Asthmapoliklin, Klin & Poliklin Dermatol Venerol & Allergol, D-10117 Berlin, Germany Asthmapoliklin Berlin Germany D-10117 Allergol, D-10117 Berlin, Germany
Titolo Testata:
HAUTARZT
fascicolo: 3, volume: 52, anno: 2001,
pagine: 205 - 210
SICI:
0017-8470(200103)52:3<205:AAFPCB>2.0.ZU;2-0
Fonte:
ISI
Lingua:
GER
Keywords:
cutaneous B cell lymphoma; treatment; anti-CD20 antibody; Rituximab (R);
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
15
Recensione:
Indirizzi per estratti:
Indirizzo: Gellrich, S Asthmapoliklin, Klin & Poliklin Dermatol Venerol & Allergol, Schumannstr 20-21, D-10117 Berlin, Germany Asthmapoliklin Schumannstr 20-21 Berlin Germany D-10117 rmany
Citazione:
S. Gellrich et al., "Anti-CD20 antibodies for primary cutaneous B cell lymphoma. Preliminary results in dermatologic patients", HAUTARZT, 52(3), 2001, pp. 205-210

Abstract

Backround and Objective. Primary cutaneous B cell lymphomas (pCBCL) are rare extracutaneous non-Hodgkin lymphomas which occur on the trunk as follicle center cell lymphoma or on the leg as large B cell lymphoma. The currently accepted therapy of pCBCL (excision and/or radiotherapy, systemic interleukin 2 and interferon alpha 2a,local injection of cisplatin or multiagent chemotherapy i.e. CHOP) is insufficient for treatment of multifocal pCBCL and secondary extracutaneous involvement. For this reason, the new synthetic chimeric, monoclonal anti-CD20 antibody Rituximab (R) is an alternative treatment for patients with pCBCL. Patients/Methods. Four patients with pCBCL localized to the trunk or head were treated with Rituximab (R) (375 mg/kg weekly for 4-8 weeks,then maintenance therapy every 4 weeks for 6 months). Results. All 4 patients showed a response (2/4 partial; 2/4 complete). Side effects were minimal. Conclusions. Rituximab (R) is an alternative immunotherapeutic drug for the treatment of pCBCL. Our initial experience with this new modality are presented and discussed.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/12/20 alle ore 09:59:56